使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Welcome to the QT Imaging third-quarter 2026 financial results conference call. (Operator Instructions) Please note, today's event is being recorded.
I'd now like to turn the conference over to your host, Tirth Patel with Investor Relations. Please go ahead.
Tirth Patel - Analyst
This is Tirth Patel with CORE IR. Thank you for participating in today's call. Joining me from QT Imaging are Dr. Raluca Dinu, Chief Executive Officer; and Jay Jennings, Chief Financial Officer. I want to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of federal securities laws.
Any statements that are not statements of historical facts should be deemed to be forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements.
All forward-looking statements are based on QT Imaging's current beliefs as well as assumptions made by and information currently available to QT Imaging. These relate to, among other things, commercialization and manufacturing of the Breast Acoustic CT scanner, the QTI Precision Pathway cloud platform, software development, reimbursement and clinical evidence initiatives, commercial distribution, international shipments, product sales growth, and projected revenue, including the 2026 revenue outlook.
For a list and description of the risks and uncertainties associated with the company's business, please see its filings with the Securities and Exchange Commission. Furthermore, the content of this call contains information that is accurate only as of the date of the live broadcast, November 10, 2026. QT Imaging disclaims any obligation, except as required by law, to update or revise any financial or operational projections or other forward-looking statements, whether because of new information, future events, or otherwise.
We will also refer to certain non-GAAP measures during the call. The definitions of these measures and reconciliations to the most directly comparable GAAP measures are available in today's earnings release. And now I'd like to turn the call over to Dr.
Raluca Dinu. Raluca?
Raluca Dinu - Chief Executive Officer, Director
Thank you, Tirth. Good afternoon, everyone. Our third-quarter results demonstrate the progress we are making in commercializing our Breast Acoustic CT imaging modality. Revenue was $7.3 million, an increase of 75% year-over-year, and we sold 15 scanners compared to nine a year ago. For the first 9 months, revenue reached $21.3 million compared to $10.7 million last year, and the scanner sales increased to $43 million from $23 million.
These results reflect meaningful growth. Our next responsibility is to translate that growth into broader clinical adoption. I want to discuss today our execution in four areas: one, US commercialization; two, clinical adoption and reimbursement; three, technology and operational scale; and four, international expansion and financial discipline. First, commercial execution.
Our US commercial business continued to gain momentum during the third-quarter, supported by a stronger direct sales organization, a significantly expanded pipeline of qualified opportunities nationwide, and the receipt of our purchase orders directly from customers across the country. We strengthened our commercial leadership structure with the three sales leaders now reporting directly into our Chief Commercial Officer, Satrajit Misra.
This expanded organization is improving our ability to engage customers, advance opportunities through the sales cycle, and convert growing market interest into purchase orders. These developments represent important progress in building a scalable US commercial operation and expanding our market presence. In parallel, we continue working with our distribution partner, NXC Imaging, a subsidiary of Canon Medical Systems USA, to improve customer placements, strengthen service execution, and drive greater commercial effectiveness.
As we finalize our 2027 commercial structure, we are focused on accelerating sales growth, strengthening customer relationships, and establishing clear accountability across both our direct sales organization and the distribution channel. Looking ahead to 2027, our current domestic distribution agreement with NXC Imaging runs through the end of this year.
We are engaged in constructive discussions with NXC and Canon Medical Systems USA regarding our future commercial relationship and scanner with the Precision Pathway SaaS platform purchase commitments. While the new agreement has not yet been finalized, we are encouraged by the progress and see opportunities to strengthen collaboration as we extend into hospitals and imaging centers.
An important part of our US commercial strategy is expanding access to large hospital networks and integrating health care systems. We also made significant progress in expanding our access to United States hospitals and health systems through Premier Inc., one of the nation's largest health care group purchasing organization or GPO.
Our Breast Acoustic CT technology was recognized at Premier Supplier Innovation Celebration following evaluation by a National Committee of Clinicians and Healthcare Supply Chain experts. Building on this recognitions in October, our distribution partner, NXC Imaging, secured a national group purchasing agreement with Premier, providing access to nearly 4,400 hospitals and health systems nationwide.
The agreement establishes pre-negotiated pricing and purchasing terms, simplifying procurement for participating providers. This significantly expands our commercial reach. Our focus now is to convert this access into purchase orders and scanner installations. Second, clinical adoption and reimbursement. On November 4, just a few days back, we achieved a major reimbursement milestone when the Centers for Medicare and Medicaid Services, or CMS, reversed its earlier proposed non-payment decision and established separate Medicare hospital outpatient payment for diagnostic QT scan examination effective January 1, 2027.
Under the final 2027 Medicare rule, CMS assigned our dedicated CPT billing code 1079T to ambulatory payment classification 5522 with payment status indicator F. Importantly, CMS recognized that physician order QT scan examination addressing specific diagnostic findings qualified under Medicare's existing diagnostic ultrasound coverage framework.
Together with the October 1 implementation of our dedicated CPT billing code, this decision removes a significant reimbursement uncertainty and establishes a clear Medicare hospital outpatient payment pathway for medically necessary diagnostic QT scan examinations. This is a very meaningful commercial milestone for QT Imaging.
Hospitals now have both a dedicated billing code and an established Medicare payment classification, strenghtening the business case for adopting our breast imaging technology. Our focus is now on translating this progress into scanner installations and clinical adoption. We have developed a comprehensive coding and billing guide to support hospitals and imaging providers while continuing our engagement with Medicare and commercial payers and expanding the clinical and economic evidence needed for broader coverage.
Medicare payment applies to medically necessary physician order diagnostic examinations rather than routine screening. We will continue pursuing additional reimbursement opportunities related to our SaaS platform and AI software improvements. An essential part of our commercial execution is ensuring that imaging centers and hospitals have access to breast radiologists properly trained to interpret the QT scan.
We have initiated a structured training program with two established radiology groups under the leadership of Dr. Mary Yamashita. This relationships will expand our clinical reading capacity and support the adoption of Breast Acoustic CT imaging modality across our growing installed base. Approximately 13,000 women have now been imaged using QT Imaging Breast Acoustic CT technology, making a significant milestone in clinical adoption and reinforcing the growing real-world foundation for advancing quantitative breast imaging.
Equally important, our multi-site repeatability reproducibility research demonstrated less than 1% variability in the speed of sound measurements under the condition studied. This finding supports the operator independent nature of our automated imaging modality, a significant advantage over conventional handheld ultrasound where image acquisition and measurements are highly dependent on operator technique and experience.
Our payer strategy builds on the newly established Medicare reimbursement pathway for medically necessary diagnostic QT scan examination and focuses on the following clinical applications: one, diagnostic evaluation of women with dense breast who require additional imaging following mammography, diagnostic evaluation of high-risk women, particularly those who face barriers to breast MRI.
Two, quantitative monitoring of response to neoadjuvant cancer therapy; and three, beyond this application, we see a significant opportunity to improve participation in the breast cancer screening. More than 30% of eligible women are not up to date with recommended screening. Our radiation-free compression-free technology has the potential to help bring these women back into the standard of care, although routine screening is not currently covered under Medicare.
We will work diligently to generate the clinical evidence to pursue the necessary regulatory approvals and expand reimbursement pathway to make QT scan accessible to more women, particularly those who face barriers to conventional breast imaging. We're aligning our clinical research programs with these priorities, working with our clinical partners to demonstrate QT scan's incremental diagnostic value potential to reduce unnecessary biopsies and ability to provide quantitative biomarkers for treatment monitoring.
Our objective is to generate the clinical and economic evidence needed to expand payer coverage, strengthen physician adoption, and accelerate broader patient access. Third, technology and operational scale. We're building an integrated breast imaging platform, not simply a manufacturing scanner. Our Breast Acoustic CT technology provides radiation-free, compression-free 3D imaging and quantitative information derived from the acoustic properties of breast tissue.
The QTI-Olea Viewer supports clinical interpretation, while QTI Precision Pathway is our cloud platform for image processing and quantitative analysis. We continue to advance our reconstruction software, improve refraction imaging quality, and streamline radiologist workflows. These investments are designed to strengthen clinical performance and support the scalability of our technology.
We strengthened our scientific leadership in July with the appointment of Dr. Julia Albright as Chief Science Officer. Her role is to connect our research, product development, and clinical evidence priorities. We also completed the relocation of our headquarters and manufacturing operations to a new, approximately 22,000 square foot facility in Petaluma, California under the leadership of our Chief Operating Officer, Steve Choate.
This expansion more than doubles our available space and has approximately doubled our scanner manufacturing capacity while significantly reducing our lease cost per square foot. The new facility allows us to streamline production, workflows, improve operational efficiency, and strengthen quality control as manufacturing volumes increase.
Importantly, this investment positions QT Imaging to support growing demand in the US and the international markets as we scale our commercial operations in 2027 and beyond. Execution at scale depends on quality. In July, we completed our first routine FDA inspection with zero form FDA 483 observations. This is an important result for our team and the systems we have put in place.
Fourth, international expansion and financial discipline. In July, we have received registration -- regulatory registration from Israel Ministry of Health, enabling commercialization in the market. We are working toward the scanner placement and clinical collaboration with Rambam Healthcare Campus focused on women with hereditary breast cancer risk.
Our international expansion reached a major milestone with our first commercial order in the Gulf Corporation Council region, GCC, secured with American Hospital Dubai through our distribution partner, Al Naghi Medical. American Hospital Dubai was the first health care institution in the Middle East to join the Mayo Clinic Care Network and operate a multi-disciplinary breast Institute integrating advanced imaging, breast surgery, oncology, pathology, and high-risk patient care.
Beyond this first commercial order, we intend to work closely with American Hospital Dubai and Al Naghi Medical on joint marketing initiatives, physician education, and clinical research evaluating the performance, patient acceptance, and quantitative tissue measurement. The clinical need in the UAE is significant. A 2023 study found that only 23% of surveyed women had undergone mammography, while separate report -- research report a median breast cancer diagnosis age of 48, while 50% presenting with locally advanced or metastatic disease.
Women die of breast cancer in UAE 12 years earlier than in the United States. We also received regulatory approval for our Breast Acoustic CT scanner in Bahrain and Qatar, further expanding our authorized market presence in the Gulf region. Together with our first commercial order from American Hospital Dubai, this milestone strengthens our foundation for commercial expansion across the GCC.
The Middle East conflict and disruption affecting regional logistics have delayed anticipated shipments to our customers and distribution partners in Saudi Arabia and the UAE. We are maintaining and further developing those relationships, but we cannot responsibly commit to a shipment date while conditions remain uncertain.
Beyond the commercial and operational milestones, October was also an important opportunity to reinforce why we're building this company. On October 2, we had the honor of ringing the NASDAQ closing bell to mark Breast Cancer Awareness month, just days after World Dense Breast Day. I emphasize the principle at the heart of QT Imaging. For decades, women have been asked to adapt to breast imaging technology.
We believe technology should adapt to women. Patient comfort matters because adherence to screening matters and women with dense breast deserve better imaging options. Our vision is to a future of breast imaging that is multi-modal, quantitative, and personalized. The NASDAQ ceremony celebrated how far we've come, but our responsibility now is to bring this technology to more physicians, more communities, and more women around the world.
We have substantially grown our revenue, strengthened our commercial organization, substantially advanced our reimbursement strategy, and expanded our manufacturing capabilities. We are building the infrastructure to bring QT Breast Acoustic CT imaging technology to more physicians and more women while maintaining our focus on commercial execution, clinical adoption, and financial discipline.
With that, I will turn the call over to Jay to review our financial results. Jay?
Jay Jennings - Chief Financial Officer
Thank you, Raluca, and good afternoon, everyone. Revenue for the third-quarter of 2026 was $7.3 million, up 75% from $4.2 million in the third-quarter of 2025. The increase was primarily attributable to sales of 15 Breast Acoustic CT scanners in the 2026 quarter compared with nine scanners in the prior year period. For the first nine months, revenue was $21.3 million compared with $10.7 million a year ago.
Gross profit for the quarter was $3 million compared with $1.8 million a year ago. Gross margin was 41.3% compared with 41.2% in the second-quarter of 2026. Total operating expenses for the quarter were $5.5 million compared with $3.5 million in the third-quarter of last year and $4.9 million in the second-quarter of 2026. As we discussed on our last call, we expected operating expenses to increase as we added commercial personnel and advanced clinical work.
third-quarter research and development expense was $1.7 million compared with $0.9 million a year ago. Selling, general, and administrative expense was $3.8 million compared with $2.5 million in the prior year quarter. Operating loss for the third-quarter was $2.4 million compared with $1.7 million in the year ago period.
Net loss was approximately $297,000 or $0.02 per share compared with a net loss of $4.6 million or $0.47 per share in the third-quarter of 2025. The smaller reported net loss reflects, in substantial part, changes in the fair values of financial liabilities. In particular, the quarter included a $2.4 million non-cash gain related to the earn-out liability compared with a $2.2 million expense in the prior year quarter.
Net cash used in operating activities during the third-quarter of 2026 was $2.2 million compared with $0.9 million during the third-quarter of 2025 and $4.8 million during the second-quarter of 2026. For the first 9 months of 2026, net cash used in operating activities totaled $10.7 million compared with $5.9 million in the prior year period. As of September 30, we had cash, cash equivalents, and restricted cash of approximately $8.4 million compared with approximately $11 million on June 30.
Now turning to our full year 2026 outlook. We are revising our revenue expectation to approximately $34 million compared with our previous guidance of approximately $39 million. The revision reflects shipment delays to our distribution partners in Saudi Arabia and the United Arab Emirates arising from the conflict in the Middle East and severe disruption to the region's normal shipping routes.
Our US scanner shipment plan is unchanged. We remain engaged with our partners, but the timing of Middle East shipments and any associated revenue recognition remain uncertain. We believe it is appropriate to reflect those conditions in our current outlook. Please refer to our third-quarter earnings release and Form 10-Q for more information about the quarter's results, liquidity, and risk factors.
And now I'll turn the call back to Raluca.
Raluca Dinu - Chief Executive Officer, Director
Thank you, Jay. In summary, our progress reflects meaningful advances across the business: one, commercial growth. It's a strong year-over-year revenue growth with 15 breast Acoustic CT scanners sold in the third-quarter and 43 during the first nine months of 2026; Two, US commercialization, a strengthened direct sales organization and expanding pipeline of qualified opportunities and continued collaboration with NXC Imaging and Canon Medical USA to accelerate customer placement;
Three, reimbursement. CMS established a separate Medicare hospital outpatient payment for diagnostic QT scan examinations effective January 1, 2027, building on the implementation of our dedicated CPT billing code in October. Four, clinical adoption. We expanded radiologist training and ongoing clinical research programs aligned with our payer strategy, focusing on supplemental breast imaging, high-risk diagnostic applications, cancer treatment response monitoring, and reabsorption of women needing breast screening into standard of care.
Five, international expansion, our first commercial order from American Hospital Dubai, regulatory approvals in Israel, Bahrain and Qatar; and progress towards clinical collaboration in this market; Number six, operational execution. The successful relocation to our expanded Petaluma headquarters and manufacturing facility doubled our capacity to support future growth;
Seven, technology innovation, continued advancement of our integrated Breast Acoustic CT platform, combining quantitative imaging, improved reconstruction software, the QTI-Olea Viewer and the QTI Precision Pathway Cloud capabilities. As we approach year-end, our priorities are clear: accelerate US commercial sales, convert our growing pipeline into purchase orders and scanners installations, expand clinical adoption, and continue building the evidence to support broader reimbursement.
While regional instability has delayed certain shipments to our Middle East customers and distribution partners, our United States commercial strategy remains on track. We are focused on delivering strong execution through the remainder of 2026 and positioning QT Imaging for continued growth in 2027. Thank you for your interest in QT Imaging and for your continued support.
With that, we are ready to take questions. Operator?
Operator
(Operator Instructions) Jeffrey Cohen, Ladenburg Thalmann.
Jeffrey Cohen - Analyst
A couple from our end. So firstly, could you talk about Q4 as far as placements and expectations? I know that based upon your commentary, you're anticipating 27 placements. Wondering beyond NXC, where you see the balance of those placements emanating from?
Raluca Dinu - Chief Executive Officer, Director
Jeff, we do expect 25 scanners sold in 2024 with 17 in the United States and the rest of them in GCC area.
Jeffrey Cohen - Analyst
Okay. Got it. And could you talk about the anticipated cost of goods for Q4? I think that you probably have already assembled some scanners. And would we see on a percentage basis, COGS for Q4 decreasing on a percentage basis?
Raluca Dinu - Chief Executive Officer, Director
Yes. COGS will -- so, first of all, the -- as you know, the gross margin for United States for our scanners is 41%. And the gross margin for the scanners are sold in -- outside the United States, in the GCC area, as the price is higher, the COGS is lower. So we do expect that the overall gross margin for the Q4 to increase rather than be exactly as we have it today for United States. Yes.
Jeffrey Cohen - Analyst
Okay. Got it. And then lastly, could you talk about the US commercial organization as it stands now with the recent adds, how many folks? And how are you characterizing by geography?
Raluca Dinu - Chief Executive Officer, Director
Yes, yes. Three senior sales VPs reporting into the commercial -- Chief Commercial Officer, Satrajit Misra, 2 of them covering the East Coast, 1 covering the West Coast. And that was, actually, absolutely an incredible progress for us to start addressing directly the customers, Jeff, on both the coasts. Obviously, the middle of the country is split equally between the sales managers of the two regions.
But we're bringing in POs ourselves, and we are obviously working collaboratively with an NXC Imaging, making sure that the sales channel is kept without noise, but very happy to have them part of the team.
Operator
Matt Hewitt, Craig-Hallum Capital Group.
Matthew Hewitt - Analyst
Maybe first up, congratulations on the CMS decision. I'm just curious what are the next steps from a reimbursement perspective, private payers, other portions of the government? Could you walk us through that, please?
Raluca Dinu - Chief Executive Officer, Director
Yes, big news from CMS. It was great to see the reimbursement news for QT scan. It's the first time in the history of this company, and it's an extraordinary news for us. The next will be the following: We will make sure that everybody is up to speed with the content of our billing and coding guide to make sure that each 1 of our clinics is aware of the fact that they can -- that the clinics can get the reimbursement from CMS.
We have already started discussions with the payers to make sure that as we get in 2027, we expand that reimbursement to other payer, Matt. A lot ahead of us, but Medicare payment for this technology is an incredible step. Hospitals can be addressed now with QT Imaging technology, imaging modality directly as much as all the other imaging modalities.
Matthew Hewitt - Analyst
Got it. That's helpful. And then regarding the Middle East, obviously, unfortunate situation. But I'm curious, once the shipping lanes do reopen, will there be a catch-up period, meaning if you're supposed to ship 5 this quarter and five next quarter, would you ship 10 as soon as things open? Or will you just get back to that kind of that expected number?
Raluca Dinu - Chief Executive Officer, Director
Matt, our plan is to ship the scanners that are lagging behind as soon as we can actually do that. We have very good relationships in both Saudi Arabia and UAE, obviously through the distributor but directly with the customers, too. The moment that we see the shipments happening, we will start addressing all those customers that are waiting for our scanners.
Matthew Hewitt - Analyst
Got it. And then maybe one final one. Regarding the US internal or direct sales team, as you look at fiscal '27, I'm sure you're just starting that planning now. But as you look at fiscal '27, is it your expectation that you will be adding resources to that team? Or do you want to kind of get these three up and running first?
Raluca Dinu - Chief Executive Officer, Director
So Matt, good question. So first of all, the three senior sales managers are doing a great job, and they'll be covering both Q1 and Q2 of next year, and they already have a very strong backlog for us to start selling into 2027. Obviously, the discussions with NXC Imaging and Canon Medical USA progressed very well, and we're going to get the news to the market at the moment that we have final terms for our agreement.
Are we going to increase our sales team? I strongly believe that we have to see the first two quarters in 2027, how we bring in the orders and how the backlog looks like to decide if we are going to increase the number of sales managers in the United States.
Operator
Pat McCann, D. Boral Capital.
Patrick McCann - Analyst
Just a couple here. First, I wanted to touch on the cash balance of, I believe, around $8 million or so at the end of the quarter and then the receivables that you collected in October. What would be your updated kind of expectations around your cash runway? How -- has that changed at all in terms of your potential need for capital and kind of how you view your ability to kind of continuing to progress with the cash you have on hand right now?
Raluca Dinu - Chief Executive Officer, Director
We pushed out some of the scanners revenue, not necessarily depleting our cash. We're very careful about the -- our cash, and we do make sure that we stay within the limits of our balance sheet, without doubt. Do we plan to go out to the market for money? Not for now. We do feel that we have to close Q4 and see how the year ends up, and then we'll decide if there is a need for accelerated growth. For now, we are on solid ground.
Patrick McCann - Analyst
And then my other question, just having to do with the issue in the Middle East. I just wanted to drill in a little bit on that. It was about, I think, what? $5 million in revenue that you kind of -- is being accounted for from the Middle East in the kind of the revision that you did for full year. I'm wondering, given that we -- it's hard for anyone to know when that situation will be resolved.
Internally, when you look at 2027, could you give any sense of how significant maybe the Middle East and those channels would be in your internal projections? I'm just trying to get a sense of what the impact could be if this situation persists for a longer term.
Raluca Dinu - Chief Executive Officer, Director
Yes, very good question. First of all, remember this, the CMS reimbursement opens up the business for QT Imaging to the hospitals. For us, there is a segment that we didn't even project in 2027. So it's a segment that we really believe will open up doors for United States business. We do have scanners planned for GCC, obviously, it's a very important segment for us. But we do believe that the business in the United States will take us to 25% growth year-over-year in revenue.
Operator
Ben Haynor, Lake Street Capital Markets.
Benjamin Haynor - Analyst
Congrats on the CMS outcome here recently. First off for me, just on kind of the medically necessary diagnostic language. I mean, is that something that applies to kind of all women with dense breast, those under 40 with a family history? What kind of group is that -- does that kind of fall up to?
Raluca Dinu - Chief Executive Officer, Director
Yes. So all women -- sorry, Ben, can you hear me? Someone on the line -- sorry. So it's diagnostic imaging. It's incremental imaging, Ben, for everybody that needs it. The -- it's not screening, and it's like we always discussed, this is -- we do not have clearance for screening, like mammography, for example, has. But we do have clearance for all women that need this imaging modality for diagnostics, which is obviously a large category of women.
As we know, Ben, 50% of women in the United States have dense breast. The cancers are hiding in dense breast. The cancers are hiding in dense breast that are being imaged by mammography. So this is where we shine.
Benjamin Haynor - Analyst
Got it. That's helpful. And then it looks like the potential hospital market with the Premier agreement not too long ago, that seems to obviously fit well with the CMS development. Have the sales folks that you have on board now, have they already started to have conversations with this channel? And if so, how are they going so far?
Raluca Dinu - Chief Executive Officer, Director
Absolutely. Our direct sales force, NXC Imaging, our distributor partner in the United States, everybody is extremely excited about the reimbursement news from CMS, definitely the relationship with Premier. We have a big year ahead of us. So we'll put our head down and execute as we've done until now.
Benjamin Haynor - Analyst
Okay. Got it. And then any plans for other international markets entering next year?
Raluca Dinu - Chief Executive Officer, Director
So Ben, first of all, we have properly develop Saudi Arabia, UAE, Israel, Bahrain, Qatar. And towards the middle of next year, we are going to get hopefully the reimbursement -- I'm sorry, the regulatory approval in Europe. It is a lot to do within a year because obviously, our main focus is the United States. And as a second priority, the growing the business in GCC countries. And after that, Europe is next. But yes, Ben, that's our focus.
Operator
And that concludes our question-and-answer session. I'd like to turn the conference back over to Dr. Raluca Dinu for closing remarks.
Raluca Dinu - Chief Executive Officer, Director
Thank you so much. I want to thank everyone for joining us today and for your continued interest in QT Imaging. We remain focused on disciplined execution as we finish the year and prepare for 2027. We look forward to discussing our progress during our next conference call. Until then, have a nice evening. Thank you so much.
Operator
Thank you. The conference has now concluded, and we thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.